Indirect comparison of sibutramine versus semaglutide for the treatment of obesity: a integrative review

Authors

  • Maria Clara Gondim Tamborenea Centro Universitário Christus (UNICHRISTUS)
  • Paloma Márjorie Alves Nogueira UNICHRISTUS
  • Pedro Sales Queiroz Estevam UNICHRISTUS
  • Juliana Saldanha Martins UNICHRISTUS
  • Tainná de Fátima Cruz dos Santos UNICHRISTUS
  • Igor da Silva Bomfim UNICHRISTUS

Keywords:

Obesity. Semaglutide. Sibutramine. Pharmacological treatment. Weight loss.

Abstract

Obesity is an endocrine-metabolic disease and currently represents a serious global health problem due to complications related to excess adiposity. It is associated with several comorbidities that reduce quality and life expectancy. Pharmacological treatment is one of the options available to aid weight loss, given the difficulties in this process and, as a consequence, reduce diseases associated with obesity and improve adherence to nutritional treatment. Therefore, this work aimed to carry out an integrative review on the indirect comparison of the drugs sibutramine and semaglutide in anti-obesity treatment, considering the wide variety of drugs available on the market and the possible related adverse effects. A bibliographical search was carried out in scientific databases focusing on comparing the effectiveness and safety in the management of obesity. The results were processed in an Excel spreadsheet and data analysis and interpretation were performed using descriptive statistics. From the results obtained, it was observed that semaglutide promoted greater weight loss and more associated benefits when compared indirectly to sibutramine.

Downloads

Download data is not yet available.

Author Biographies

Maria Clara Gondim Tamborenea, Centro Universitário Christus (UNICHRISTUS)

Graduada em Nutrição.

Paloma Márjorie Alves Nogueira , UNICHRISTUS

Estudante do curso de Nutrição.

Pedro Sales Queiroz Estevam, UNICHRISTUS

Estudante do curso de Nutrição.

Juliana Saldanha Martins, UNICHRISTUS

Estudante de Nutrição.

Tainná de Fátima Cruz dos Santos , UNICHRISTUS

Estudante do curso de Enfermagem.

Igor da Silva Bomfim, UNICHRISTUS

Doutor e mestre em Farmacologia pela Universidade Federal do Ceará - FAMED/UFC, ênfase no estudo do potencial anti-câncer de novas moléculas em modelos pré-clínicos. Graduado em Enfermagem e com especialização em Farmacologia Clínica. Tem experiência no ensino das disciplinas: Fisiopatologia em Pneumologia e cardiologia; Farmacologia Básica e Clínica; Fisiologia Humana; Patologia geral; Fisiopatologia; Doenças Infecto-parasitárias; Cuidado Integral à Saúde do Adulto; Bioquímica; Oncologia e Toxicologia. Docente da Unichristus nos cursos de Enfermagem, Biomedicina e Nutrição, nas disciplinas: Bioquímica; Fisiologia; Farmacologia e Oncologia. Professor de Fisiopatologia, Oncologia Clínica; Farmacologia médica I e II; Sistemas orgânicos integrados no curso de Medicina da Faculdade Estácio de Canindé, ESTÁCIO, Brasil. Coordenador acadêmico do curso de especialização em Oncologia Clínica no Centro Universitário

Published

2025-03-31

Issue

Vol. 14 No. 3 (2024): Scire Salutis - Ago, Set, Out 2024

Section

Farmacologia

License

Copyright (c) 2024 Scire Salutis

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

The CBPC - Companhia Brasileira de Produção Científica (Brazil CNPJ: 11.221.422/0001-03) the material rights of the published works. The rights relate to the publication of the work anywhere in the world, including rights to renewals, expansions and dissemination of the contribution, as well as other subsidiary rights. All electronically published works may subsequently be published in printed collections under the coordination of this company and / or its partners. The authors preserve the copyright, but are not allowed to publish the contribution in another medium, printed or digital, in Portuguese or in translation.